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ABSTRACT
Patients with diabetes mellitus (DM) are prone
to a diffuse and accelerated form of coronary
artery disease (CAD), which in turn is a major
cause of cardiac-related morbidity and
mortality. Compared with patients without
diabetes, patients with diabetes undergoing
coronary revascularization are at higher risk of
procedural, short-, and long-term
cardiovascular events and mortality. Although
coronary artery bypass grafting (CABG) has
been regarded as the primary revascularization
strategy in diabetic patients with complex CAD,
percutaneous coronary intervention (PCI) is an
effective revascularization alternative, due to
remarkable advances in stent devices and
adjunctive drug therapies. Outcomes data,
from subgroup analyses and small-sized
clinical trials and large registries, have
suggested that PCI with current stent
technology showed comparable long-term
risks of mortality and hard endpoints, but
higher risk of repeat revascularization for the
diabetic population compared to CABG.
However, the recent landmark International
Future REvascularization Evaluation in patients
with diabetes mellitus: optimal management of
Multivessel disease (FREEDOM) trial provides
compelling evidence of the superiority of CABG
over PCI in reducing the rates of death,
myocardial infarction, at the expense of
stroke, in patients with diabetes with
advanced CAD. When opting for PCI in
patients with diabetes, currently used drug-
eluting stents (DES) are more efficient in
reducing the risk of repeat revascularization
without compromising safety outcomes,
compared to bare-metal stents. The selection
R. E. Harskamp
Academic Medical Center, University of
Amsterdam, Amsterdam, The Netherlands
R. E. Harskamp  D.-W. Park
Duke Clinical Research Institute, Duke University
Medical Center, 2400 Pratt St., Durham, NC 27715,
USA
D.-W. Park (&)
Department of Cardiology, University of Ulsan
College of Medicine, Asan Medical Center, 388-1
Poongnap-dong, Songpa-gu, Seoul 138-736, Korea
e-mail: dwpark@amc.seoul.kr
Enhanced content for this article is
available on the journal web site:
www.cardiologytherapy-open.com
123
Cardiol Ther (2013) 2:69–84
DOI 10.1007/s40119-013-0014-3
of a specific type of DES in patients with
diabetes is controversial and therefore more
data comparing second- and newer-generation
DES for patients with diabetes are currently
needed. Also, efforts to make more advanced
DES platforms suitable for patients with
diabetes with complicated angiographic
features are still ongoing.
Keywords: Coronary artery bypass grafting;
Coronary artery disease; Diabetes mellitus;
Drug-eluting stents; Percutaneous coronary
intervention
INTRODUCTION
Over the last decades, the prevalence of diabetes
mellitus (DM) has significantly increased
worldwide [1]. Coronary artery disease (CAD)
is a major cause of morbidity and mortality
among patients with DM. Compared to
individuals without diabetes, those with
diabetes have a higher prevalence of CAD,
present at an earlier age, and have a greater
extent of coronary atherosclerosis [2].
Due to the aggressive form of CAD, a large
proportion of diabetic patients require intensive
medical treatment and surgical or percutaneous
coronary revascularization, and therefore
optimal decision-making on medical and
revascularization strategies of significant CAD
is crucial to obtain better long-term outcomes
in such patients.
For patients with diabetes requiring coronary
revascularization, coronary artery bypass
grafting (CABG) has been considered the
preferred revascularization strategy because of
concerns regarding higher risk of restenosis and
ischemic cardiovascular complications, and
uncertainty of very long-term durability of
percutaneous coronary intervention (PCI) [3].
However, with rapid advancements of novel
PCI devices, techniques, and adjunctive drug
therapy, clinical results of PCI for patients with
diabetes have been markedly improved, and
also newer technologies are continuously
developing to enhance clinical outcomes in
diabetic patients with complex clinical and
angiographic characteristics [4].
In this review of the literature, the key
clinical studies comparing medical,
percutaneous, or surgical management for
diabetic patients with CAD have been
summarized, and the authors also compare
PCI outcomes among several stent types in
patients with diabetes. This review provides
valuable information for optimal selection of
revascularization strategy as well as PCI devices
for patients with diabetes with higher clinical
and angiographic risk profiles.
MATERIALS AND METHODS
The authors searched PubMed, Embase, and the
Cochrane Central Register of Controlled Trials
(CENTRAL) for randomized clinical trials and
prospective or retrospective observational
studies using the terms: ‘‘diabetes mellitus,’’
‘‘revascularization,’’ ‘‘coronary artery bypass
grafting,’’ ‘‘percutaneous coronary intervention,’’
‘‘antiplatelet therapy,’’ and the names of
individual stent systems (bare-metal stents,
sirolimus-eluting stents, paclitaxel-eluting
stents, everolimus-eluting stents, zotarolimus-
eluting stents, biodegradable polymer drug-
eluting stents, and bioabsorbable coronary
stents) until November 2012. We also checked
the reference lists of review articles, meta-
analyses, and original studies identified by the
electronic searches to find other eligible studies
for systemic reviews. There was no language
restriction for the search. In addition, we
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searched conference proceedings/abstracts from
the American Heart Association, American
College of Cardiology, Transcatheter
Cardiovascular Therapeutics, Society of
Cardiovascular Angiography and Intervention,
European Society of Cardiology, and Euro-PCR.
Two authors (R.E.H., D.W.P.) collaboratively
assessed studies eligibility for this systemic review.
DISCUSSION
Diabetic Impact on Outcomes after CABG
and PCI
Outcomes after surgical or percutaneous
revascularization are uniformly worse in
patients with diabetes as compared to those
without diabetes. The presence of diabetes has
negatively affected outcomes following CABG
surgery and so the rates of death and adverse
cardiovascular events after CABG were
significantly higher in patients with diabetes
compared to those without diabetes. An analysis
from the Society of Thoracic Surgery database
(n = 146,786) showed early (30-day) mortality of
3.7% in patients with diabetes following CABG,
compared with 2.7% in those without diabetes
(adjusted odds ratio: 1.23, 1.15–1.32) [5]. In
particular, patients with diabetes requiring
insulin therapy were at higher risk (adjusted
odds ratio: 1.39, 1.27–1.52) than those on oral
hypoglycemic medications (adjusted odds ratio:
1.13, 1.04–1.23) as compared with patients
without diabetes. Diabetes is also associated
with more perioperative noncardiac morbidity,
including ischemic or hemorrhagic stroke, renal
failure, infections, and longer length of hospital
stay. Infection, particularly mediastinitis due to
impaired sternal wound healing, is of particular
concern in patients with diabetes [6]. This risk
may be reduced by maintenance of strict glycemic
control during the perioperative period. The need
for additional revascularization by graft failure is
also more common in patients with diabetes
following CABG [7].
Similarly to what is observed in patients
undergoing CABG surgery, diabetes is also
associated with poorer clinical outcomes after
PCI. Although the procedural success rates are
relatively similar in patients with and without
diabetes, patients with diabetes have higher rates
of restenosis and long-term cardiovascular events
than patients without diabetes [8–10]. Similarly to
a significantly higher rate of restenosis in patients
with diabetes undergoing bare-metal stent (BMS)
implantation than patients without diabetes (31%
vs. 21%, P\0.001) [8], a large registry using
sirolimus-eluting stents (SES) showed an
incremental increase of target-lesion
revascularization (TLR) at 3 years according to
the severity of diabetic status (10% in patients
without diabetes, 14% in patients with
noninsulin-dependent diabetes, and 19% in
patients with insulin-dependent diabetes) [11].
Diabetes is also associated with higher rates of
myocardial infarction (MI) and mortality
following PCI. An observational study with BMS
showed survival rates (91.7% vs. 96.2%) and
freedom from MI (89.9% vs. 94.4%) was
significantly lower in the diabetic population
than in the nondiabetic population [12].
Similarly, observation registry with drug-eluting
stent (DES) showed that 3-year mortality was
significantly higher in patients with diabetes
than in those without (17.3% vs. 7.8%) [13].
Some studies suggest that the clinical impact of
diabetes may vary among various ethnic
populations [17–19].
Optimal Treatment Selection: Medical
Versus Revascularization
Optimal treatment for patients with both type 2
DM and stable CAD has been controversial. The
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best available evidence regarding optimal
therapy for patients with diabetes with stable
angina is derived from the Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI
2D) Trial [14], in which 2,368 patients with
diabetes with significant CAD were randomized
to undergo either prompt revascularization with
intensive medical therapy or intensive medical
therapy alone, and to undergo either insulin-
sensitization or insulin-provision therapy.
Primary results showed no difference in long-
term mortality and major adverse cardiac events
(MACE; a composite of death, MI, or stroke)
between patients with intensive medical
treatment and those with prompt (surgical or
percutaneous) revascularization. In the PCI
stratum, there was no significant difference in
primary endpoints between the
revascularization group and the medical
therapy group. However, in the CABG stratum,
the rate of MACE was significantly lower in the
revascularization group than in the medical
therapy group (22.4% vs. 30.5%, P = 0.01),
mainly driven by markedly fewer incidences of
nonfatal MI in the revascularization group than
in the medical therapy group (7.4% vs. 14.6%).
Figure 1 summarizes the relative treatment
effect between intensive medical treatment alone
and prompt initial coronary revascularization
among total population, PCI-eligible patients,
and CABG-eligible patients. However, BARI 2D
was not designed to address whether PCI may
produce outcome results similar to those of CABG
in patients with extensive CAD. These
comparisons have been recently addressed via
important randomized clinical trials.
Optimal Treatment Selection: CABG
Versus PCI
Two decades ago, a substudy of the BARI Trial
(n = 353) showed a significant survival
advantage of CABG over PCI with only
balloon angioplasty at 5-year follow-up (5.8%
vs. 20.6%, P = 0.0003) [15]. The diabetic
subgroup analysis (n = 208) of the Arterial
Revascularization Therapies Study (ARTS) Trial
comparing BMS and CABG for multivessel CAD
showed that PCI was significantly associated
with a higher rate of repeat revascularization,
but hard clinical endpoints were not different
among the two revascularization strategies at
5-year follow-up [16]. A pooled analysis of
individual patient data from 10 randomized
trials suggested that among patients with
diabetes, mortality was lower in the surgical
group (n = 615) than in the PCI group (n = 618)
(23% vs. 29%, hazard ratio [HR] = 0.70,
0.56–0.87) [17]. In contrast, registry data
showed that patients with diabetes and
multivessel disease had non-significant
adjusted outcomes (death: HR = 0.97, P = 0.75,
death or MI: HR = 0.84, P = 0.07) following PCI
with DES (n = 3,256) compared with CABG
(n = 2,844) [18].
Table 1 summarizes current evidence of
clinical trials comparing DES and CABG for
diabetic patients with multivessel CAD. In
subgroup analysis of the Synergy Between
Percutaneous Coronary Intervention with
Taxus and Cardiac Surgery (SYNTAX) Trial,
452 patients had medically treated diabetes,
221 treated with CABG and 231 treated with
PCI with paclitaxel-eluting stents (PES) [19]. At
1 year, the composite safety endpoint (death,
stroke, or MI) was comparable between CABG
and PCI for patients with diabetes (10.3% vs.
10.1%) and without diabetes (6.8% vs. 6.8%).
But, MACE (death, MI, stroke, or repeat
revascularization) difference between two
treatment options (CABG vs. PCI) was
significantly pronounced in patients with
diabetes (14.2% vs. 26.0%, P = 0.003) than in
patients without diabetes (11.8% vs. 15.1%,
72 Cardiol Ther (2013) 2:69–84
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Fig. 1 5-year outcomes for death, cardiac death, MI, and
the composite endpoints of death or MI, or of cardiac death
or MI according to initial treatment strategy, and to
percutaneous coronary intervention and coronary artery
bypass grafting strata. Data are derived from The Bypass
Angioplasty Revascularization Investigation 2 Diabetes
(BARI 2D) Trial. The Kaplan–Meier method was used
to assess 5-year event rates. CABG coronary artery bypass
grafting, IMT intensive medical therapy, MI myocardial
infarction, PCI percutaneous coronary intervention























































































































































































































































































































































































































































































































































































































































































































































































































































74 Cardiol Ther (2013) 2:69–84
123
P = 0.08), which was mainly driven by higher
repeat revascularization. The Coronary Artery
Revascularization in Diabetes (CARDia) Trial
was a diabetes-specific trial; 254 patients were
treated with CABG and 256 patients with PCI.
Primary endpoint (death, MI, or stroke) at 1 year
was similar between the two groups. But, MACE
including revascularization was significantly
higher in the PCI group [20]. However,
previous SYNTAX subgroup analysis and
CARDia Trial were just hypothesis-generating
or severely underpowered and therefore the
evidence to guide the choice between CABG
and PCI for patients with diabetes was very
limited before the results from the International
Future REvascularization Evaluation in patients
with diabetes mellitus: optimal management of
Multivessel disease (FREEDOM) Trial [21].
The FREEDOM Trial enrolled 1,900 patients
with diabetes with multivessel CAD who were
randomly assigned to either CABG or PCI using
first-generation DES and the primary outcome
measure was hard clinical endpoint (composite
of death from any cause, nonfatal MI, or
nonfatal stroke). At 5 years, the primary
composite outcome occurred significantly
more often in the PCI group than in the
CABG group (26.6% vs. 18.7%, P = 0.005). The
benefit of CABG was driven by differences in
rates of both MI (6.0% vs. 13.9%, P\0.001) and
death from any cause (10.9% vs. 16.3%,
P = 0.049). However, stroke was more frequent
in the CABG group (5.2% vs. 2.4%, P = 0.03). As
expected, PCI was associated with significantly
higher rates of repeat revascularization (12.6%
vs. 4.8%; HR = 2.74, 95% CI 1.91–3.89). These
findings were consistent among various high-
risk subgroups (high SYNTAX score, low
ejection fraction, and impaired renal function).
In clinical practice, the decision on coronary
revascularization strategy in patients with
diabetes should be based on the extent of
CAD, ischemic burden, ventricular function,
clinical comorbidities, and patient’s agreement.
In those with multivessel disease, who can
tolerate CABG surgery and have lesions that
carry high risk for PCI, surgical
revascularization would be the preferred
approach. For patients with diabetes with
single-vessel disease or less complex
multivessel CAD, PCI with DES would be a
reasonable alternative of standard CABG.
Currently, based on compelling evidence of
the FREEDOM Trial, the threshold for selection
of CABG over PCI would be much lower in
patients with diabetes than in those without.
However, since first-generation DES were
predominantly used in the FREEDOM trial,
whether outcomes may be improved with the
use of new-generation DES is a matter of debate,
and therefore future trials comparing second- or
newer-generation DES and CABG should be
performed to reassess the relative treatment
effect in patients with diabetes.
PCI in Diabetes
BMS Versus First-Generation DES
Patients with diabetes have a higher burden of
atherosclerosis, smaller coronary arteries, larger
extents of diseased segments, and a higher risk
of repeat revascularization after PCI than do
patients without diabetes. Considering the
marked improvement of efficacy regarding
restenosis and repeat revascularization, the use
of DES is preferable to the use of BMS for
diabetic patients with complex angiographic
features and higher tendency of restenosis. The
selection of a specific type of DES in patients
with diabetes is still controversial.
The relative efficacy and safety of first-
generation DES (SES and PES) compared to
BMS in patients with diabetes have been
evaluated in many of the early stent trials. A
Cardiol Ther (2013) 2:69–84 75
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collaborative network meta-analysis of 35 trials
comparing BMS, SES, and PES, which included
3,852 patients with diabetes, showed that that
DES were as safe as BMS in patients with
diabetes when dual antiplatelet therapy was
prescribed for 6 months or more. In addition,
the reduction in the risk of repeat
revascularization was significantly lower in SES
and PES compared to BMS and the risk with the
use of DES in patients with diabetes was similar
to the risk reduction in patients without
diabetes [22].
By contrast, in a real-world registry including
5,051 adult patients with DM undergoing PCI
(3,341 treated with DES and 1,710 treated with
BMS), there was a significant reduction in risk-
adjusted mortality (17.5% vs. 20.7%; P = 0.02),
MI (13.8% vs. 16.9%; P = 0.02), and repeat
revascularization (18.4% vs. 23.7%; P\0.001)
associated with DES versus BMS at 3-year long-
term follow-up [23].
First-Generation DES: SES Versus PES
The relative efficacy and safety of SES and PES in
patients with diabetes has been evaluated in
several clinical studies. The direct and indirect
network analysis showed that there was no
difference found in death or MI between SES
and PES in patients with diabetes, but the rate of
repeat revascularization was lower after use of
SES compared with PES [22]. In contrast, a
subsequent meta-analysis of over 12,000
patients with diabetes including several
randomized controlled trials (RCT) and
observational studies showed that the risks of
MACE and repeat revascularization were similar
between PES and SES [24]. In a subset of 13
RCTs, the rates for MACE (PES: 15.4% vs. SES:
12.9%) and TLR (PES: 8.6% vs. SES: 7.6%) were
similar between two stents, and in subset of 16
registries, the rates for MACE (PES: 10.1% vs.
SES: 11.9%) and target-vessel revascularization
(TVR) (PES: 5.8% vs. SES: 7.2%) were also
similar. Recently, long-term results of a meta-
analysis including six RCTs comparing SES and
PES in diabetic population showed that the use
of SES was significantly associated with 35%
reduction of TLR compared to PES, but there
were no differences of safety outcomes in terms
of death or MI, and stent thrombosis at a
median follow-up of 4 years [25].
Second-Generation DES
Since early-generation DES had been widely
used and long-term safety issues had been
raised, new platforms for DES that are aimed at
improving safety and efficacy have been
developed. First-generation DES released
sirolimus or paclitaxel and had stainless-steel
platforms, whereas new-generation DES release
zotarolimus or everolimus and feature cobalt–
chrome or platinum–chrome platforms with
thinner strut thickness and more
biocompatible, durable polymer coatings.
These new-generation stents have almost
replaced first-generation DES in routine clinical
practice, and SES is no longer manufactured.
In comparison of Endeavor zotarolimus-
eluting stents (ZES) (Medtronic, Inc., Santa
Rosa, CA, USA) with a first-generation DES, a
substudy of the ENDEAVOR IV Clinical Trial: A
Trial of a Coronary Stent System in Coronary
Artery Lesions (known as ENDEAVOR IV) (477
diabetic population) showed that 1-year clinical
outcomes were similar (target-vessel failure
(TVF): 8.6% vs. 9.4%) after Endeavor ZES and
PES [26]. By contrast, a diabetic subgroup of the
Scandinavian Organization for Randomized
Trials With Clinical Outcome III (SORT-OUT
III) Trial showed that implantation of Endeavor
ZES compared to an SES is associated with a
considerably increased risk of the MACE (18.3%
vs. 4.8%) and repeat revascularization at
18-month follow-up [27]. A subgroup analysis
76 Cardiol Ther (2013) 2:69–84
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of the Comparison of the Efficacy and Safety of
Zotarolimus-Eluting Stent versus Sirolimus-
Eluting Stent and PacliTaxel-Eluting Stent for
Coronary Lesions (ZEST) Trial (n = 760 diabetic
population) comparing Endeavor ZES versus SES
and PES showed that primary endpoint (death,
MI, TVR) at 12 months after use of Endeavor
ZES were similar to the PES (13.8% vs. 15.3%),
but was significantly higher compared to SES
(13.8% vs. 7.7%) [28]. Recently, in the Patient-
Related Outcomes with Endeavor versus Cypher
Stenting Trial (PROTECT), involving 8,791
patients comparing Endeavor ZES with SES,
there was no difference in the primary
endpoint of definite or probable stent
thrombosis at 3 years [29]. Similarly, the risk
of death or MI was similar with the two types of
DES. In a prespecified diabetic subgroup
analysis (n = 2,410), similar findings were
observed. However, the risk of repeat
revascularization was significantly higher with
Endeavor ZES.
In several randomized trials, everolimus-
eluting stent (EES) improved clinical outcomes
as compared with PES, reducing the risks of
repeat revascularization, MI, and stent
thrombosis; the Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent
System (SPIRIT) II [30] (n = 300, 23.1%
diabetes), SPIRIT III [31] (n = 1,002, 29.0%
diabetes), SPIRIT IV [32] (n = 3,687, 32.4%
diabetes) and the Comparison of the
everolimus-eluting XIENCE-V stent with the
paclitaxel-eluting TAXUS LIBERTE´ stent in all-
comers: a randomized open label trial
(COMPARE) [33] (n = 1,799, 18.1% diabetes).
Merged analyses of these clinical trials
compared the relative treatment effect of EES
and PES according to the diabetic status [34].
Compared to the remarkable benefit of EES over
PES in patients without diabetes, no significant
differences of clinical outcomes were seen
between the two stent types in patients with
diabetes. A significant interaction was found
between the presence of diabetes and stent type
for the 2-year occurrence of MI (P = 0.01), stent
thrombosis (P = 0.0006), and ischemia-driven
TLR (P = 0.02). Further studies might be
required to explain the underlying mechanism
of diabetic-related interaction on clinical
outcomes according to different DES types.
Randomized comparisons showed similar
outcomes for EES and SES with respect to rates
of death, MI, and repeat revascularization, and
these results were also maintained in diabetic
population [35, 36]. The randomized
comparison of everolimus-eluting stent versus
sirolimus-eluting stent implantation for de
novo CAD in patients with diabetes mellitus
(ESSENCE-DIABETES) Trial [37], which was
specifically designed to evaluate EES versus SES
in 300 patients with diabetes, showed
noninferiority of EES to SES in reducing in-
segment late loss and angiographic restenosis at
8 months. However, in 1-year clinical outcomes
of ischemia-driven TLR, death and MI showed
similar outcomes. In the Interventional
Cardiology Research In-Cooperation Society-
Drug-Eluting Stents (IRIS-DES) Registry [38],
6,166 consecutive patients who received either
EES or SES were enrolled and 34.8% (2,145) were
diabetics. This study showed that 2-year MACE
in the overall group as well as the diabetic group
was similar. In contrast to a significant
interaction between diabetic status and EES
versus PES, no such interaction was found
among EES versus SES.
A newer-version of ZES, the ResoluteTM ZES
(Medtronic, Inc. Santa Rosa, CA, USA) was
developed using a dual polymer technology
that extends the release of zotarolimus and drug
exposure to the vessel to 4 months [44]. Among
several second-generation DES, the Resolute ZES
has been approved as specific indication for
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patients with diabetes by the United States Food
and Drug Administration, based on a
prespecified analysis from the Resolute US
clinical trial in which the outcome for death,
MI, and TLR was similar to patients without
diabetes [39]. The Resolute ZES was compared
with the EES in two large-scale trials; A
Randomized Comparison of a Zotarolimus-
Eluting Stent With an Everolimus-Eluting
Stent for Percutaneous Coronary Intervention
(RESOLUTE All Comers) Trial [40], and a
randomized controlled trial in second-
generation zotarolimus-eluting Resolute stents
versus everolimus-eluting Xience V stents in
real-world patients: the TWENTE Trial [41],
which showed similar risks of cardiac death,
MI, repeat revascularization, and stent
thrombosis throughout a 2-year period. In a
diabetic subgroup of each trial, HRs for primary
endpoint nonsignificantly favored EES rather
than Resolute ZES (RESOLUTE All Comer; 1.45
[0.82–2.59], P = 0.25 and TWENTE; 1.81
[0.91–3.60], P = 0.08). However, due to the
nature of subgroup analysis, these findings are
considered to be primarily hypothesis-
generating and more specific clinical trials
comparing Resolute ZES and EES targeting the
diabetic population are warranted.
A recent network meta-analysis comparing
outcomes with various DES (SES, PES, EES, and
ZES) or BMS in 22,844 patients with diabetes
showed that currently used DESs are more
efficient at reducing the risk of TLR without
compromising safety outcomes, as compared
with BMS [42]. There are considerable
differences in the relative efficacy and safety
profiles of various DESs and EES seems to be the
most efficient and the safest of the currently
available DES in patients with diabetes. Figure 2
illustrates the probability of several DES and
BMS producing the best outcomes in terms of
efficacy and safety endpoints for patients with
Fig. 2 Several stents comparisons (drug-eluting stents and
bare-metal stents) for patients with diabetes. BMS bare-
metal stents, Def/prob ST deﬁnite or probable stent
thrombosis, DES drug-eluting stent, EES everolimus-
eluting stents, MI myocardial infarction, PES paclitaxel-
eluting stents, SES sirolimus-eluting stents, TVR target-
vessel revascularization, ZES zotarolimus-eluting stents.
Comparing data for Resolute ZES is limited
78 Cardiol Ther (2013) 2:69–84
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diabetes. However, more data comparing EES,
Resolute EES, and biodegradable polymer DES
for diabetic patients are currently required, and
no definitive conclusion regarding the
comparative propensity for safety and efficacy
outcomes with specific DES for diabetic
population can be derived from current
available data.
To overcome the proinflammatory stimulus
of durable polymers, biodegradable polymer-
based DESs have been developed. Theoretically,
this platform would be more useful for patients
with diabetes with complicated anatomic
features predisposing to stent thrombosis and
long-term safety issues. The primary results of
the Limus Eluted from A Durable versus
ERodable Stent coating (LEADERS) Trial
showed similar safety and effectiveness of
biodegradable polymer biolimus-eluting stent
(BES) compared with durable polymer SES at
9 months [43]. The relative treatment effects
were consistent in patients with (rate ratio 1.03,
95% CI 0.61–1.75) and without (rate ratio 0.78,
95% CI 0.54–1.14) diabetes. These findings were
maintained up to 4 years [44]. A fully
bioabsorbable DES temporarily scaffolds the
vessel wall and then disappears once the acute
recoil and constrictive remodeling processes
have subsided [45]. If sufficient clinical data
are obtained in future clinical trials, this system
might be very useful especially for diabetic
patients with a higher chance of being treated
with subsequent CABG. Currently, there are still
very limited data regarding the general
performance and outcomes of bioabsorbable
DES for patients with diabetes.
Adjunctive Drug Therapies in Diabetic
Patients Receiving PCI
The effect of glycemic control on PCI outcomes
among diabetic patients has been investigated
in previous study [46]. This study suggested that
the rate of clinical restenosis after PCI in
patients with diabetes might be significantly
lower if optimal glycemic control was achieved;
patients with diabetes with a preprocedural
glycosylated hemoglobin (HbA1c) of B7% had
a similar rate of 1-year TVR compared patients
without diabetes (15% vs. 18%), whereas
patients with diabetes with an HbA1c [7%
had a significantly higher rate of TVR (34%).
Experimentally, thiazolidinediones have been
suggested to suppress intimal proliferation after
vascular injury. The potential efficacy of this
approach in diabetic patients undergoing PCI
has been evaluated in two small randomized
trials using pioglitazone [47] or rosiglitazone
[48] and lower rates of angiographic restenosis
were found in the experimental group.
However, due to limited sample size and lack
of clinical benefit, larger studies are needed for
definite conclusions.
Dual antiplatelet therapy with aspirin and a
P2Y12 inhibitor reduces the risk of ischemic
events after stent placement. However, as
compared with patients without diabetes, the
efficacy of antiplatelet agents is significantly
reduced in patients with diabetes, due to
platelet hyper-reactivity and relatively poor
response to antiplatelet therapy [49, 50]. Until
now, several studies testing novel antiplatelet
agents suggested that platelet inhibition could
be further enhanced among patients with
diabetes receiving PCI. Results of diabetic
subgroup analyses from major pharmacologic
clinical trials comparing prasugrel [51, 52],
ticagrelor [53], high-dose clopidogrel [54], and
vorapaxar [55], as compared to standard
clopidogrel therapy are shown in Table 2.
Overall, although it was not always statistically
significant, treatment effect favored new
antiplatelet agents or regimens over standard
regimen.
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In subgroup analyses the relative efficacy and
safety of glycoprotein (GP) IIb/IIIa inhibitors in
patients with diabetes appear to be similar to
those without diabetes [56, 57]. In contrast, two
meta-analyses using pooled trial data suggested
that patients with diabetes may benefit more
than those without diabetes with a significant
mortality reduction at 30 days and 1 year
[58, 59]. However, the diabetic-specific
Intracoronary Stenting and Antithrombotic
Regimen: Is Abciximab a Superior Way to
Eliminate Elevated Thrombotic Risk in
Diabetics (ISAR-SWEET) Trial [60], in which 701
diabetic patients were randomized to receive
abciximab versus placebo add-on conventional
heparin and 600 mg clopidogrel loading,
showed that the primary endpoint of death or
MI at 1-year follow-up did not differ between the
two groups (8.3% vs. 8.6%), and there was no
difference in mortality (4.8% vs. 5.1%).
CONCLUSIONS
For patients with diabetes with significant CAD,
the decision when and how to proceed to
coronary revascularization should be based on
multiple parameters including patient
characteristics, comorbidities, clinical
presentation, coronary anatomy and lesion
complexity, ischemic burden, left ventricular
function, and patients preference. Since
decision-making in patients with diabetes is
frequently complicated, such a decision is
reasonable to be made after discussion in a
multidisciplinary ‘‘heart team.’’ Based on
compelling evidence of the FREEDOM Trial,
the threshold for selecting CABG over PCI
would be lower in patients with diabetes than
in patients without.
With marked advances of stent device
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with DES has become one of the efficient
revascularization strategies for patients with
diabetes. Compared with BMS, the currently
used DES are more efficacious at reducing the
risk of restenosis and repeat revascularization
without compromising safety outcomes,
including mortality and late stent thrombosis
in patients with diabetes. Among several DES,
network meta-analysis indirectly suggest that
EES seems to be the most efficacious and safest
for use in patients with diabetes. However, since
direct comparison trials among EES, Resolute,
biodegradable polymer DES, and newer versions
of DES for patients with diabetes are limited, the
selection of a specific type of DES in patients
with diabetes is still controversial.
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